INIS 10-Q
Radnostix Inc (INIS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from _____________ to _______________
Commission file number:
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ý
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ¨ | Accelerated filer ¨ |
| Smaller reporting company | |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ¨
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨
Yes ý
As of November 11, 2022, the number of shares of common stock, $0.01 par value, outstanding was .
| 1 |
INTERNATIONAL ISOTOPES INC.
Form 10-Q
For The Quarter Ended September 30, 2022
TABLE OF CONTENTS
| Page No. | ||
| PART I – FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | |
| Unaudited Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021 | 3 | |
| Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 | 4 | |
| Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 | 5 | |
| Unaudited Statement of Reconciliation of Stockholder’s (Deficit) Equity for the Three and Nine Months Ended September 30, 2022 and 2021 | 6 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 8 | |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 4. | Controls and Procedures | 27 |
| PART II – OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 27 |
| Item 1A. | Risk Factors | 27 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 27 |
| Item 6. | Exhibits | 28 |
| Signatures | 29 | |
| 2 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(unaudited)
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable | ||||||||
| Inventories | ||||||||
| Prepaids and other current assets | ||||||||
| Total current assets | ||||||||
| Long-term assets | ||||||||
| Restricted cash | ||||||||
| Property, plant and equipment, net | ||||||||
| Capitalized lease disposal costs, net | ||||||||
| Financing lease right-of-use asset | ||||||||
| Operating lease right-of-use asset | ||||||||
| Goodwill | ||||||||
| Patents and other intangibles, net | ||||||||
| Total long-term assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Unearned revenue | ||||||||
| Current portion of operating lease right-of-use liability | ||||||||
| Current portion of financing lease liability | ||||||||
| Current portion of related party notes payable, net of debt discount | ||||||||
| Current installments of notes payable | ||||||||
| Current portion of mandatorily redeemable preferred stock, net of debt discount | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities | ||||||||
| Accrued long-term liabilities | ||||||||
| Related party notes payable, net of current portion and debt discount | ||||||||
| Notes payable, net of current portion | ||||||||
| Asset retirement obligation | ||||||||
| Financing lease liability, net of current portion | ||||||||
| Operating lease right-of-use liability, net of current portion | ||||||||
| Mandatorily redeemable convertible preferred stock, net of current portion and discount | ||||||||
| Total long-term liabilities | ||||||||
| Total liabilities | ||||||||
| Stockholders' equity | ||||||||
| Common stock, $ par value; shares authorized; and shares issued and outstanding respectively | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total equity | ||||||||
| Total liabilities and stockholders' equity | $ | $ | ||||||
See accompanying notes to consolidated financial statements
| 3 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Operations
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Sale of product | $ | $ | $ | $ | ||||||||||||
| Cost of product | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating costs and expenses | ||||||||||||||||
| Salaries and contract labor | ||||||||||||||||
| General, administrative and consulting | ||||||||||||||||
| Research and development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Net operating income (loss) | ( | ) | ( | ) | ( | ) | ||||||||||
| Other income (expense): | ||||||||||||||||
| Other income | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other (expense) income | ( | ) | ( | ) | ( | ) | ||||||||||
| Net (loss) income | ( | ) | ( | ) | ( | ) | ||||||||||
| Less income attributable to noncontrolling interest | ||||||||||||||||
| Net (loss) income attributable to International Isotopes Inc. | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||
| Net loss per common share - basic: | $ | $ | $ | $ | ||||||||||||
| Net loss per common share - diluted: | $ | $ | $ | $ | ||||||||||||
| Weighted average common shares outstanding - basic: | ||||||||||||||||
| Weighted average common shares outstanding - diluted: | ||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 4 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine months ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net (loss) income | $ | $ | ( | ) | ||||
| Adjustments to reconcile net (loss) income to net Cash provided by operating activities | ||||||||
| Depreciation and amortization | ||||||||
| Accretion of obligation for lease disposal costs | ||||||||
| Accretion of beneficial conversion feature and discount | ||||||||
| Equity based compensation | ||||||||
| Gain on sale of property, plant, and equipment | ( | ) | ||||||
| Right-of-use asset amortization | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventories | ||||||||
| Prepaids and other current assets | ||||||||
| Accounts payable and accrued liabilities | ( | ) | ||||||
| Unearned revenues | ( | ) | ||||||
| Net cash provided by operating activities | ( | ) | ||||||
| Cash flows from investing activities: | ||||||||
| Proceeds from sale of property, plant and equipment | ||||||||
| Purchase of property, plant, and equipment | ( | ) | ( | ) | ||||
| Net cash (used in) provided in investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from sale of stock and exercise of options and warrants | ||||||||
| Payments on financing lease | ( | ) | ( | ) | ||||
| Distributions to non-controlling interest | ( | ) | ||||||
| Proceeds from the issuance of notes payable | ||||||||
| Principal payments on notes payable | ( | ) | ( | ) | ||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | ( | ) | ||||||
| Cash, cash equivalents, and restricted cash at beginning of period | ||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow activities: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Supplemental disclosure of noncash financing and investing transactions | ||||||||
| Decrease in accrued interest and increase in equity for conversion of dividends to stock | $ | $ | ||||||
| Increase in operating lease right-of-use asset and right-of-use liability for new lease | $ | $ | ||||||
| Increase in equity and decrease in liability for the conversion of preferred stock | $ | $ | ||||||
| Non-cash increase of capitalized ARO for increased funding plan | $ | $ | ||||||
| Decrease in unearned revenue and increase in notes payable for repayment plan | $ | $ | ||||||
| Increase in equity and decrease in Non-controlling interest for acquisition of non controlling interest in RadQual and TI Services | $ | $ | ||||||
Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:
| September 30, | September 30, | |||||||
| 2022 | 2021 | |||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash included in long-term assets | ||||||||
| Total cash, cash equivalents, and restricted cash shown in statement of cash flows | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 5 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Reconciliation of Stockholders' (Deficit) Equity
Three and Nine Months Ended September 30, 2022
(Unaudited)
| Equity | ||||||||||||||||||||||||
| Attributable | ||||||||||||||||||||||||
| Common stock | to | |||||||||||||||||||||||
| Additional | Internat'l | Total | ||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | (Deficit) | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Equity | |||||||||||||||||||
| Balance, January 1, 2022 | ( | ) | ||||||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||
| Stock grant | ( | ) | ||||||||||||||||||||||
| Stock in lieu of dividends on convertible preferred C | ||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||
| Warrant exercise | ||||||||||||||||||||||||
| Conversion of preferred B stock | ||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||
| Net (loss) income | — | |||||||||||||||||||||||
| Balance, September 30, 2022 | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||
| Equity | ||||||||||||||||||||||||
| Attributable | ||||||||||||||||||||||||
| Common stock | to | |||||||||||||||||||||||
| Additional | Internat'l | Total | ||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | (Deficit) | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Equity | |||||||||||||||||||
| Balance, July 1, 2022 | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||
| Net (loss) income | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||
| Balance, September 30, 2022 | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements
| 6 |
Three and Nine Months Ended September 30, 2021
(Unaudited)
| Equity | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| Common stock | to | Attributable | ||||||||||||||||||||||||||
| Additional | Internat'l | to | Total | |||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, January 1, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Stock grant | ( | ) | ||||||||||||||||||||||||||
| Stock in lieu of dividends on convertible preferred C | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Warrant exercise | ( | ) | ||||||||||||||||||||||||||
| Conversion of preferred C stock | ||||||||||||||||||||||||||||
| Conversion of preferred B stock | ||||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Shares issued for purchase of 75.5% of RadQual | ( | ) | ||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | ( | ) | ( | ) | |||||||||||||||||||||||
| Net (loss) income | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Balance, September 30, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Equity | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| Common stock | to | Attributable | ||||||||||||||||||||||||||
| Additional | Internat'l | to | Total | |||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, July 1, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Conversion of preferred C stock | ||||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Shares issued for purchase of 75.5% of RadQual | ( | ) | ||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | ( | ) | ( | ) | |||||||||||||||||||||||
| Net (loss) income | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Balance, September 30, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements
| 7 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements
September 30, 2022
(1) The Company and Basis of Presentation
International Isotopes Inc. (INIS) was incorporated
in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting
principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly owned
subsidiaries, including RadQual, LLC (RadQual) and TI Services, LLC (TI Services). TI Services is headquartered in Youngstown, Ohio and
was formed with RadQual in December 2010 to distribute products and services for nuclear medicine, nuclear cardiology, and Positron Emission
Tomography (PET) imaging. RadQual is a global supplier of molecular imaging quality control and calibration devices, and is headquartered
in Idaho Falls, Idaho. In August 2017, affiliates of INIS purchased
Nature of Operations – The Company manufactures a full range of nuclear medicine calibration and reference standards, generic sodium iodide I-131 drug product, cobalt teletherapy sources, and a varied selection of radiochemicals for medical research, and clinical applications. For 2022, the Company’s business consists of four business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. Due to minimal activity, the Radiological Services business segment was reorganized into the Company’s Nuclear Medicine Standards segment as of January 1, 2022. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.
With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s condensed consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.
Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. See Note 4 “RadQual Acquisition” for additional information regarding RadQual and TI Services. All significant intercompany accounts and transactions have been eliminated in consolidation.
Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three or nine-month periods ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022.
Recent Accounting Pronouncements – In August 2020, the Financial Accounting Standards Board issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). The update simplifies accounting related to convertible debt instruments. The standard is effective for fiscal years beginning after December 15, 2023 including interim periods within those fiscal years. INIS is currently evaluating the effect this standard will have on its financial statements.
(2) Current Developments and Liquidity
Business Condition – Since inception,
the Company has incurred substantial losses. During the nine months ended September 30, 2022, the Company reported net income of $
| 8 |
During the nine months ended September 30, 2022, the Company continued its focus on its strongest long-standing core business segments which consist of its radiochemical products, cobalt products, and nuclear medicine standards, and in particular, the pursuit of new business opportunities within those segments.
Additionally, the Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility and a property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier, and the Company considers it a valuable asset.
For the nine months ended September 30, 2022, the Company had stock options outstanding, and outstanding shares of Series C Preferred Stock, each of which were not included in the computation of diluted income per common share because they would be anti-dilutive. The Company used the treasury stock method in calculating weighted average common shares diluted.
For the three months ended September 30, 2022, the Company had stock options outstanding, and outstanding shares of Series C Preferred Stock, each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive. The Company used the treasury stock method in calculating weighted average common shares diluted.
For the three and nine months ended September 30, 2021, the Company had stock options outstanding, warrants outstanding, outstanding shares of Series B redeemable convertible preferred stock (Series B Preferred Stock), and outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.
| 3 Months Ended | 9 Months Ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Weighted average common shares outstanding - basic | ||||||||||||||||
| Effects of dilutive shares | ||||||||||||||||
| Stock Options | ||||||||||||||||
| Weighted average common shares outstanding - diluted | ||||||||||||||||
The table below summarizes common stock equivalents outstanding at September 30, 2022 and 2021:
| September 30, | ||||||||
| 2022 | 2021 | |||||||
| Stock options | ||||||||
| Warrants | ||||||||
| Shares of Series B redeemable convertible preferred stock | ||||||||
| Shares of Series C redeemable convertible preferred stock | ||||||||
(4) RadQual Acquisition
On July 8, 2021, the Company
entered into a Membership Interest Purchase Agreement (the Purchase Agreement) with RadQual and the sellers set forth in the Purchase
Agreement, which included the Company’s Chairman of the Board, Chief Executive Officer, former Chairman of the Board, and certain
other stockholders of the Company (collectively, the “Sellers”). Pursuant to the Purchase Agreement, the Company acquired
all of the outstanding membership interests of RadQual not then owned by the Company for an aggregate purchase price of approximately
$
| 9 |
(5) Sale of Assets
In February 2022, the Company
entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which the Company sold certain assets for $
(6) Inventories
At September 30, 2022 and December 31, 2021, the company
held inventories of $
Inventories consisted of work in process for the following business segments:
| September 30, 2022 | December 31, 2021 | |||||||
| Radiochemical Products | $ | $ | ||||||
| Cobalt Products | ||||||||
| Nuclear Medicine Products | ||||||||
| $ | $ | |||||||
When indicators of inventory impairment exist, the Company measures the carrying value of the inventory against its market value, and if the carrying value exceeds the market value, the inventory value is adjusted down accordingly. No impairment was recorded for the nine months ended September 30, 2022 or 2021.
(7) Stockholders’ Equity, Options, and Warrants
Employee Stock Purchase Plan
The Company has an employee stock purchase plan pursuant
to which employees of the Company may participate to purchase shares of common stock at a discount. During the nine months ended September
30, 2022 and 2021, the Company issued and shares of common stock, respectively, to employees under the employee stock
purchase plan for proceeds of $
Stock-Based Compensation Plans
2015 Incentive Plan - In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the 2015 Plan), which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 Plan by an additional shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards. At September 30, 2022, there were shares available for issuance under the 2015 Plan.
Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by recognizing compensation expense based on the grant date fair value of the award. Stock option compensation expense is recognized over the vesting period for the award.
| Fixed Options | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value | ||||||||||||
| Outstanding at December 31, 2021 | $ | |||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Expired | ( | ) | ||||||||||||||
| Forfeited | ( | ) | ||||||||||||||
| Outstanding at September 30, 2022 | $ | $ | ||||||||||||||
| Exercisable at September 30, 2022 | $ | $ | ||||||||||||||
| 10 |
The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $ per share on September 30, 2022, the last trading day of the quarter.
As of September 30, 2022, there was $ of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of years.
Total stock-based compensation expense for the nine months ended September 30, 2022 and 2021 was $ and $ respectively. Total stock-based compensation expense for the three-months ended September 30, 2022 and 2021 was $59,769 and $11,578, respectively.
During the nine months ended September 30, 2022, the Company granted an employee qualified stock options with an exercise price of $ per share and another qualified stock options with an exercise price of $ per share to one of its employees. These options vest over a -year period with the first vesting at the one-year anniversary of the grant and expiration at ten-year anniversary for all grants. On February 21, 2022, the Compensation Committee granted qualified stock options to the Company’s executive officers and non-qualified stock options to members of the Board. The exercise price for these options was $ per share. The remaining executive officer and board member . All these granted options expire at the ten-year anniversary of the grant. The options issued during the nine months ended September 30, 2022 have a fair value of $ as estimated on the date of issue using the Black-Scholes options pricing model with the following weighted-average assumptions: risk free interest rate of % to %, expected dividend yield rate of %, expected volatility of % to % and an expected life between and years.
In March 2022, qualified stock options were exercised under a cashless exercise. The company withheld shares to satisfy the exercise price and issued shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the accompanying unaudited condensed consolidated financial statements.
In August 2022, qualified stock options were exercised under a cashless exercise. The company withheld shares to satisfy the exercise price and issued shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the accompanying unaudited condensed consolidated financial statements.
Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded fully vested shares of common stock to its Chief Executive Officer in February 2022 under the 2015 Plan. The number of shares awarded was based on a $ stock award using a price of $ per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2021, which was $ per share. The Company withheld shares of common stock to satisfy payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2022 totaled .
Warrants
As of September 30, 2022, there are no outstanding
warrants. On February 14, 2022, Class M Warrants were exercised for an exercise price of $
Warrants outstanding at September 30, 2021, included
Preferred Stock
On May 31, 2022, the Company paid with shares of the Company’s common stock all outstanding Series B Preferred Stock outstanding with a mandatory redemption date of May 2022 at $ per share or $. The May 31, 2022 average price of the Company’s common stock was $ per share. The Company issued shares of common stock to satisfy the $ redemption amount.
| 11 |
At September 30, 2022, there were shares of
the Series C Preferred Stock outstanding with a
During the nine
months ended September 30, 2022 and 2021 dividends paid to holders of the Series C Preferred Stock totaled $
(8) Debt
In December 2013, the Company entered into a promissory
note agreement with its then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $
In April 2018,
the Company borrowed $
In December 2019 and February 2020, the Company borrowed $ from four of the Company’s major shareholders pursuant to a promissory note (the 2019 Promissory Note). The 2019 Promissory Note bears an interest rate of % annually and is due . According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling warrants to purchase shares of the Company’s common stock at $ per share (the Class O Warrants). The fair value of these Class O Warrants issued totaled $ and was recorded as a debt discount and will be amortized over the life of the 2019 Promissory Note. The Company calculated a beneficial conversion feature of $ which will be accreted to interest expense over the life of the 2019 Promissory Note. At September 30, 2022, the balance of the 2019 Promissory Note was $, The remaining debt discount was $, the remaining beneficial conversion feature was $, and the accrued interest on the 2019 Promissory Note totaled $.
In April 2021, the Company
borrowed $
| 12 |
(9) Commitments and Contingencies
Dependence on Third Parties
The production of High Specific Activity Cobalt is
dependent upon the Department of Energy (DOE), and its prime operating contractor, which controls the Advanced Test Reactor (ATR) and
laboratory operations at the ATR located outside of Idaho Falls, Idaho.
Sales of our most predominant radiochemical products are dependent upon a few key suppliers. An interruption in production by any of these individual suppliers could have an immediate negative impact upon radiochemical sales until material could be purchased from alternate suppliers including obtaining regulatory approval to use material from alternative suppliers if necessary.
The Nuclear Medicine Reference and Calibration Standard products sold by the Company are dependent upon certain radioisotopes that are supplied to the Company through agreements with several suppliers. A loss of any of these suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.
Contingencies
Because all the Company’s business segments
involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained
staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted
within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or
projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would
permit processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this
license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted
money market account held with Merrill Lynch in the amount of $
| 13 |
(10) Revenue Recognition
Revenue from Product Sales
The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:
| Three Months Ended September 30, 2022 | Three Months Ended September, 2021 | |||||||||||||||||||||||||
| U.S. | Outside U.S. | Total Revenues | % of Total Revenues | U.S. | Outside U.S. | Total Revenues | % of Total Revenues | |||||||||||||||||||
| Radiochemical Products | $ | $ | $ | % | $ | $ | $ | % | ||||||||||||||||||
| Cobalt Products | % | % | ||||||||||||||||||||||||
| Nuclear Medicine Products | % | % | ||||||||||||||||||||||||
| Fluorine Products | % | % | ||||||||||||||||||||||||
| $ | $ | $ | % | $ | $ | $ | % | |||||||||||||||||||
| Nine Months Ended September 30, 2022 | Nine Months Ended September 30, 2021 | |||||||||||||||||||||||||
| U.S. | Outside U.S. | Total Revenues | % of Total Revenues | U.S. | Outside U.S. | Total Revenues | % of Total Revenues | |||||||||||||||||||
| Radiochemical Products | $ | $ | $ | % | $ | $ | $ | % | ||||||||||||||||||
| Cobalt Products | % | % | ||||||||||||||||||||||||
| Nuclear Medicine Products | % | % | ||||||||||||||||||||||||
| Fluorine Products | % | % | ||||||||||||||||||||||||
| $ | $ | $ | % | $ | $ | $ | % | |||||||||||||||||||
The Company’s revenue consists primarily of
distribution of radiochemicals including sodium iodide I-131 drug product, calibration and reference standards manufactured for use in
the nuclear medicine industry, and cobalt source manufacturing. With the exception of certain unique products, the Company’s normal
operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating
cycle for those products is considered to be two to three years. Accordingly, preliminary payments
received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on
the Company’s condensed consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated
ship dates. For the nine months ended September 30, 2022, the Company reported current unearned revenue of $
Accounts Receivable
The Company records a receivable when it has an unconditional
right to receive consideration after the performance obligations are satisfied. As of September 30, 2022, and December 31,
2021, accounts receivable totaled $
(11) Leases
The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.
| 14 |
| Nine Months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Operating lease costs | $ | $ | ||||||
| Short-term operating lease costs | ||||||||
| Financing lease expense: | ||||||||
| Amortization of right-of-use assets | ||||||||
| Interest on lease liabilities | ||||||||
| Total financing lease expense | ||||||||
| Total lease expense | $ | $ | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $ | $ | ||||||
| Right-of-use assets obtained in exchange for new financing lease liabilities | $ | $ | ||||||
| Weighted-average remaining lease term (years) - operating leases | ||||||||
| Weighted-average remaining lease term (years) - financing leases | ||||||||
| Weighted-average discount rate - operating leases | % | % | ||||||
| Weighted-average discount rate - financing leases | % | % | ||||||
| Operating | Financing | |||||||
| 2022 (excluding the nine-months ended September 30, 2022) | $ | $ | ||||||
| 2023 | ||||||||
| 2024 | ||||||||
| 2025 | ||||||||
| 2026 | ||||||||
| Thereafter | ||||||||
| Total minimum operating lease obligations | ||||||||
| Less-amounts representing interest | ( | ) | ( | ) | ||||
| Present value of minimum operating lease obligations | ||||||||
| Current maturities | ( | ) | ( | ) | ||||
| Lease obligations, net of current maturities | $ | $ | ||||||
(12) Segment Information
The Company has
| 15 |
Information regarding the operations and assets of these reportable business segments is contained in the following table:
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Sale of Product | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate revenue | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Depreciation and Amortization | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate depreciation and amortization | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Segment Income (Loss) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ( | ) | ( | ) | ||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Fluorine Products | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total Segments | ||||||||||||||||
| Corporate loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net (Loss) Income | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Expenditures for Segment Assets | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate purchases | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
| September 30, | December 31, | |||||||
| Segment Assets | 2022 | 2021 | ||||||
| Radiochemical Products | $ | $ | ||||||
| Cobalt Products | ||||||||
| Nuclear Medicine Standards | ||||||||
| Fluorine Products | ||||||||
| Total Segments | ||||||||
| Corporate assets | ||||||||
| Total Consolidated | $ | $ | ||||||
| 16 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as “anticipates,” “believes,” “should,” “expects,” “future,” “intends” and similar expressions identify forward-looking statements. Forward-looking statements reflect management’s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 31, 2022 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by applicable law. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.
BUSINESS OVERVIEW
International Isotopes Inc., its wholly owned subsidiaries, including RadQual, LLC and TI Services, LLC (collectively, the Company, we, our, or us) manufacture a full range of nuclear medicine calibration and reference standards, manufacture a range of cobalt products, and distribute sodium iodide I-131 as a generic drug. We own 100% interest of RadQual, LLC (RadQual), a global supplier of molecular imaging quality control and calibration devices.
RADQUAL ACQUISTION
On July 8, 2021, we entered into a Membership Interest Purchase Agreement (the Purchase Agreement) with RadQual and the sellers set forth in the Purchase Agreement, which included our Chairman of the Board, Chief Executive Officer, former Chairman of the Board, and certain other stockholders of the Company (collectively, the Sellers). Pursuant to the Purchase Agreement, we acquired all of the outstanding membership interests of RadQual not then-owned by the Company for an aggregate purchase price of approximately $4.4 million, payable in shares of our common stock valued at $0.11 per share (determined by the average trading price of our common stock on the OTC Markets during the 60 trading day period immediately prior to June 2, 2021) (the RadQual Acquisition). We issued an aggregate of 40,176,236 shares of its common stock to the Sellers as consideration in the RadQual Acquisition. Prior to the RadQual Acquisition, we owned approximately 24.5% of the outstanding membership interests of RadQual, and after acquiring all of the remaining membership interests of RadQual, RadQual became a wholly-owned subsidiary of the Company. The RadQual Acquisition closed on July 8, 2021.
Our business consists of the following four business segments in 2022 and consisted of five business segments in 2021:
Nuclear Medicine Standards. Our Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These sources are used for indication of patient positioning, SPECT and PET camera operational testing, and calibration of dose measurement equipment. Revenue from nuclear medicine products includes consolidated sales from TI Services, LLC (TI Services), a joint venture that we formed with RadQual in December 2010 to distribute our products. Our nuclear medicine standards products include a host of specially designed items used in the nuclear medicine industry. In addition to the manufacture of these products, we have developed a complete line of specialty packaging for the safe transport and handling of these products. Beginning January 1, 2022, this segment also includes miscellaneous source disposal activities that were previously reported as part of the Radiological Services segment.
Cobalt Products. Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. We are the only company in the U.S. that can provide all these unique services. There has been a significant increase in regulation by the Nuclear Regulatory Commission (NRC) in recent years that has created a significant barrier to new entrants into this market. The Company has a contract in place with the U.S. Department of Energy (DOE) for the production of high specific activity cobalt in the Advanced Test Reactor (ATR) in Idaho. This agreement will be in effect until October 2024.
| 17 |
Radiochemical Products. Our Radiochemical Products segment includes production and distribution and FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. We are the only U.S. Company distributing this generic drug product. This segment also includes distribution of certain other radiochemical products and contract manufacturing of radiopharmaceutical products for our customers.
Fluorine Products. We established the Fluorine Products segment in 2004 to support production and sale of the gases that we expected to produce using our Fluorine Extraction Process (FEP) in conjunction with the operation of the proposed depleted uranium de-conversion facility in Lea County, New Mexico. Near the end of 2013, due to changes in the nuclear industry, we placed further engineering work on this project on hold. We continue to hold discussions with potential future customers seeking this type of service, however, further development activity within this segment will be deferred until market and industry conditions change to justify resuming design and construction of the facility. In the meantime, the Company expects to continue to incur some costs associated with the maintenance of licenses and other necessary project investments, and to continue to keep certain agreements in place that will support resumption of project activities at the appropriate time.
Radiological Services. Our Radiological Services segment consisted of a wide variety of miscellaneous services such as decommissioning disused irradiation units, performing sealed source exchanges in irradiation and therapy units, and gemstone processing. The Company has suspended all of its field service activities and has terminated most gemstone processing. Due to decreased activity in this segment, starting January 1, 2022, this segment was reorganized into our Nuclear Medicine Standards segment. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.
COVID-19 AND COST INFLATION UPDATE
As a result of the COVID-19 pandemic, we experienced a reduction of sales within our nuclear medicine calibration standards segment and radiochemicals segment during 2021. There was no discernable impact from COVID-19 to our cobalt products business segment during the period. The decrease in sales for 2021 for our nuclear medicine calibration standards segment was the result of the temporary closure of many imaging clinics and suspension of elective or non-essential imaging procedures. During the three months ended March 31, 2022, we experienced some global shipping disruption that were partially attributable to the COVID-19 pandemic. The decrease in sales in our nuclear medicine calibration standards segment for the nine months ended September 30, 2022, is partially due to these shipping disruptions.
To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. We have only seen a limited impact in our raw material supply chain related to the COVID-19. From the beginning of 2022, we have experienced an increase in costs for many raw materials and production supplies due to recent cost inflation which have led to increases to costs of goods sold and operating expenses. Although, all segments have been impacted from these cost increases, our nuclear medicine calibration standards segment has been impacted the most. We have seen these increased costs stabilize somewhat; and we are working on counteracting these cost increases with an increase to our produce prices. We believe we can increase our sales prices enough to overcome these cost increases while continuing to maintain and grow our sales.
RESULTS OF OPERATIONS
Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021
Revenue for the three months ended September 30, 2022 was $2,789,273 as compared to $2,617,514 for the same period in 2021, an overall increase of $171,759, or approximately 7%. This increase in revenue was the result of increased revenue in our Radiochemical Products, Cobalt Products, and Nuclear Medicine Standards segments, as discussed in detail below.
The following table presents a period-to-period comparison of total revenue by segment for the three months ended September 30, 2022 and 2021:
For the three- months ended September 30, | For the three- months ended September 30, | |||||||||||||||
| Sale of Product | 2022 | 2021 | $ change | % change | ||||||||||||
| Radiochemical Products | $ | 1,298,667 | $ | 1,210,615 | $ | 88,052 | 7 | % | ||||||||
| Cobalt Products | 424,731 | 408,808 | 15,923 | 4 | % | |||||||||||
| Nuclear Medicine Standards | 1,065,875 | 990,328 | 75,547 | 8 | % | |||||||||||
| Fluorine Products | — | 7,763 | (7,763 | ) | -100 | % | ||||||||||
| Total Consolidated | $ | 2,789,273 | $ | 2,617,514 | $ | 171,759 | ||||||||||
| 18 |
Cost of sales increased to $1,305,730 for the three months ended September 30, 2022 from $1,006,334 for the same period in 2021. This is an increase of $299,396, or approximately 30%. The increase in cost of sales in the three-month comparison was primarily due to the increased sales activity in all our business segments along with increases in the cost of raw materials and supplies driven by recent cost inflation, as discussed in detail below. Gross profit for the three months ended September 30, 2022 was $1,483,543, compared to $1,611,180 for the same period in 2021. This represents a decrease in gross profit of $127,637, or approximately 8%. Our Gross profit percentage for the three months ended September 30, 2022 was 53%, compared to 62% for the same period in 2021. This decrease in gross profit percentage is a result of increased cost in raw material and supplies driven by recent cost inflation, as discussed in detail below.
The following table presents cost of sales and gross profit data for each of our business segments for the three months ended September 30, 2022 and 2021:
For the three- months ended September 30, | % of Total Sales | For the three- months ended September 30, | % of Total Sales | |||||||||||||
| 2022 | 2022 | 2021 | 2021 | |||||||||||||
| Total Sales | $ | 2,789,273 | $ | 2,617,514 | ||||||||||||
| Cost of Sales | ||||||||||||||||
| Radiochemical Products | $ | 498,210 | 18 | % | $ | 459,344 | 17 | % | ||||||||
| Cobalt Products | 232,679 | 8 | % | 148,855 | 6 | % | ||||||||||
| Nuclear Medicine Standards | 574,841 | 21 | % | 398,135 | 15 | % | ||||||||||
| Fluorine Products | — | 0 | % | — | 0 | % | ||||||||||
| Total Segments | 1,305,730 | 47 | % | 1,006,334 | 38 | % | ||||||||||
| Gross Profit | $ | 1,483,543 | $ | 1,611,180 | ||||||||||||
| Gross Profit % | 53 | % | 62 | % | ||||||||||||
Operating expense increased approximately 22% to $1,957,096 for the three months ended September 30, 2022, from $1,609,758 for the same period in 2021. This increase of $347,338, is due to an increase of 23% in Salaries and Contract Labor expense, and increase of 14% in General, Administrative, and Consulting expenses, and a 101% increase in Research and Development costs. The increase in Salaries and Contract Labor costs is a result of an increased number of employees and increases to labor rates incurred during the three months ended September 30, 2022, as compared to the same period in 2021. The increase in General, Administrative, and Consulting expenses is due to periodic waste disposal costs that occurred in the three months ended September 30, 2022. The 101% increase in Research and Development cost is due to increased activity in product development during the three months ended September 30, 2022, as compared to the same period in 2021.
The following table presents a comparison of total operating expense for the three months ended September 30, 2022 and 2021:
For the three- months ended September 30, | For the three- months ended September 30, | |||||||||||||||
| Operating Costs and Expenses: | 2022 | 2021 | % change | $ change | ||||||||||||
| Salaries and Contract Labor | $ | 800,550 | $ | 650,065 | 23 | % | $ | 150,485 | ||||||||
| General, Administrative and Consulting | 1,008,219 | 885,807 | 14 | % | 122,412 | |||||||||||
| Research and Development | 148,327 | 73,886 | 101 | % | 74,441 | |||||||||||
| Total operating expenses | $ | 1,957,096 | $ | 1,609,758 | 22 | % | $ | 347,338 | ||||||||
Other income was $49,151 for the three months ended September 30, 2022, as compared to $54,083 for the same period in 2021. This is a decrease of $4,932, or approximately 9%. In September 2022, we experienced a fraudulent transactions incident. The fraudulent charges totaled approximately $85,000. These charges were recorded as “other expense”. Investigations by our bank and by law enforcement are ongoing. There have been no indications of any involvement within our Company. As we expected to recoup all fraudulent changes from our bank, for the three months ending September 30, 2022, we recognized "other income" to offset the fraudulent charges recorded under “other expense”. In October and November 2022, we recovered all of the fraudulent charges from our bank.
Interest expense for the three months ended September 30, 2022 was $147,116, compared to $191,544 for the same period in 2021. This is a decrease of $44,428, or approximately 23%. Interest expense includes dividends accrued on our Series C Redeemable Convertible Preferred Stock (Series C Preferred Stock). As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the three months ended September 30, 2022, we accrued dividends payable of $60,945, which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $26,548 for the
| 19 |
accretion of the beneficial conversion feature of the 2019 Promissory Note (as defined below) and $37,518 for the issuance of warrants in conjunction with the 2019 Promissory Note were recorded for the three months ended September 30, 2022. See Note 7 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.
Our net loss for the three months ended September 30, 2022, was $568,669, compared to net loss of $136,869, for the same period in 2021. This is an increase in loss of $431,800 is largely the result of the increase in Cost of Sales in our Cobalt products and Nuclear Medicine Standards segments to the increase in operating expenses for the three months ended September 30, 2022, as compared to the same period in 2021.
Radiochemical Products. Revenue from the sale of Radiochemical Products for the three months ended September 30, 2022 was $1,298,667, compared to $1,210,615 for the same period in 2021. This is an increase of $88,052, or approximately 7% during the three months ended September 30, 2022. The increase is the result of continued increased sales of our generic sodium iodide I-131 drug product. We expect continued sales growth for our Radiochemical products going forward.
Cost of sales for Radiochemical Products increased to $498,210 for the three months ended September 30, 2022, as compared to $459,344 for the same period in 2021. This is an increase of $38,866, or approximately 8%, and was the result of increased sales of product. Gross profit of radiochemical products for the three months ended September 30, 2022 was $800,457, compared to $751,271, for the same period in 2021. Gross profit percentage was approximately 62% for the three months ended September 30 for both 2022 and 2021. Operating expense for this segment decreased to $346,234 for the three months ended September 30, 2022, compared to $380,684 for the same period in 2021. This decrease in operating expense of $34,450, or approximately 10%, was primarily due to decreased costs for production supplies, and depreciation expense. This segment reported net income of $454,223 for the three months ended September 30, 2022, as compared to net income of $370,586 for the same period in 2021. The increase in net income of $83,637 is the result of the increase in revenue.
Cobalt Products. Revenue from the sale of Cobalt Products for the three months ended September 30, 2022 was $424,731, compared to $408,808, for the same period in 2021. This represents an increase of $15,923, or approximately 4%. The increase was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at somewhat random times throughout the year. Frequently the timing of these sales can have a significant impact on period over period comparisons.
In October 2014, we entered into a ten-year agreement with the DOE for the irradiation of cobalt targets. It takes many years to irradiate these cobalt targets to the desired level of activity and we anticipated having high specific activity cobalt available for our customers in 2020. However, the material had lower than expected activity and further receipt of material was delayed until about June 2021. At that point the material still had lower than expected activity, and we reached an agreement with the DOE to purchase the material at a discounted rate. Periodically we have been able to acquire recycled material that can be used to manufacture sealed sources for customers, and in some instances, our customers have supplied their own cobalt material for source fabrication. We also have access to additional low specific activity material produced by the DOE and expect to obtain, process, and sell additional cobalt products as a result during the remainder of 2022.
We have entered into cobalt purchase agreements with several customers. Pursuant to these contracts, we will supply some bulk cobalt-60 and provide sealed source manufacturing for the customers. The terms of these cobalt contracts require some advance progress payments from each customer. The funding received under these contracts has been recorded as unearned revenue under short- and long-term liabilities in our consolidated financial statements. For the three months ended September 30, 2022 and 2021, we recognized approximately $10,000 and $1,500, respectively when we fulfilled contract performance objectives by supplying sealed sources manufactured with cobalt from the ATR or alternate suppliers.
Cost of sales for the three months ended September 30, 2022, was $232,679, as compared to $148,855, for the same period in 2021. Gross profit for cobalt products for the three months ended September 30, 2022, was $192,052 compared to $259,953 for the same period in 2021. This is a decrease of $67,901, or approximately 26% and is attributable to an increased labor and material cost in source manufacturing for the three months ended September 30, 2022, as compared to the same period in 2021. Our gross profit percentages were approximately 45% and 64% for the three-month periods ended September 30, 2022 and 2021, respectively. The decrease in the gross profit percentage for the three months ended September 30, 2022 is primarily due to increased costs of raw material and labor used in the manufacture of sealed sources. Operating expense in this segment increased to $326,096 for the three months ended September 30, 2022, from $93,145 for the same period in 2021. This is an increase of $232,951, or approximately 250%. This increase in operating expenses for the three months ended September 30, 2022 is due to waste disposal expense of approximately $215,000. Our manufacturing processes generate some radioactive waste. The estimated costs of storage and disposal of these materials have been included in the manufacturing and sales price of our products. However, actual disposal costs are subject to change at the discretion of the disposal site and are ultimately applied at the time of disposal. Our net loss for Cobalt Products was $134,044 for the three months ended September 30, 2022, as compared to a net income of $166,808 for the same period in 2021. The decrease in income of $300,852, or approximately 180%, was attributable to an increased cost of materials from cobalt sealed source manufacturing due to recent cost inflation and due to increased operating expenses for waste disposal.
| 20 |
Nuclear Medicine Standards. Revenue from Nuclear Medicine Standards for the three months ended September 30, 2022, was $1,065,875, compared to $990,328 for the same period in 2021. This represents an increase in revenue of $75,547, or approximately 8%.
Cost of sales for our Nuclear Medicine Standards segment for the three months ended September 30, 2022, was $574,841, as compared to $398,135 for the same period in 2021. The increase in cost of sales in the period-to-period comparison of $176,706, or 44%, was due to increased sales activity and increased costs for supplies and raw materials during the three-month period ended September 30, 2022, as compared to the same period in 2021. Gross profit for our nuclear medicine standards segment for the three months ended September 30, 2022 was $491,034 compared to $592,193 for the same period in 2021, and gross profit percentages were approximately 46% and 60% for the three months ended September 30, 2022 and 2021, respectively. This is a decrease in gross profit of $101,159, or approximately 17%. The decrease in gross profit in the period-to-period comparison is primarily the result of increased costs for supplies and raw materials attributable to cost inflation. We expect these increased costs to continue going forward, and we are adjusting our sales prices accordingly.
Operating expense for this segment for the three months ended September 30, 2022 decreased to $425,863, from $459,008 for the same period in 2021. This is a decrease of 33,145, or approximately 7%, and is the result of decreased marketing and consulting fees in the three months ended September 30, 2022. Operating expenses includes non-controlling member interest expense attributable to RadQual and TI Services of $0 for the three months ended September 30, 2022 compared with $4,275 for the three months ended September 30, 2021. In July 2021, we purchased the remaining 75.5% interest in RadQual; this resulted in RadQual and TI Services becoming our fully owned subsidiaries. Net income for this segment for the three months ended September 30, 2022 was $65,171, compared to net income $133,185 for the same period in 2021. This decrease in net income of $68,014, or approximately 51% and is primarily the result of increased costs for supplies and raw materials attributable to cost inflation.
Radiological Services. Starting in 2022, due to drastically decreased activity in the segment, all remaining activities in our Radiological Services is reported in our Nuclear Medicine Standards segment.
In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service substantially occurred in 2021 and the Company saw a steady decline in revenue from this service as production was wrapped up. In the first half of 2022, we converted the spaces in the facility that were previously used to perform this contract work into expanded Nuclear Medicine new product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.
Revenue from field service work for the DOE had accounted for the majority of revenue in this segment. However, Radiological Field Services work was terminated in 2020 and we did not generate any Radiological Field Services revenue in 2021 or 2022. We have removed this type of activity from our NRC license and do not expect to perform this in future years.
We continue to engage in source disposal activities and have begun reporting these activities under the Nuclear Medicine Standards segment starting January 1, 2022. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.
Fluorine Products. For the three months ended September 30, 2022, we had no revenue for our Fluorine Products segment as compared to $7,763 for the three months ended September 30, 2021. Revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. The agreement concluded in 2021. During the three months ended September 30, 2022, we incurred $37,204 of expense related to items in support of future planning and design for the proposed de-conversion facility, as compared to $34,348 for the same three-month period in 2021. This is an increase of 8% in the period-to-period comparison and is the result of increased professional services costs related to exploring options for possible renewal of work on this project.
We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our FEP. The project has been placed on hold since 2013 and we will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials until such time that we decide to resume the project.
Nine Months Ended September 30, 2022 Compared to Nine Months Ended September 30, 2021
Revenue for the nine-month period ended September 30, 2022 was $8,031,522, as compared to $7,369,922 for the same period in 2021, an increase of $661,600, or approximately 9%. The performance of all our business segments for the nine-month period is discussed in further detail below.
| 21 |
The following table presents a period-to-period comparison of total revenue by segment for the nine months ended September 30, 2022 and September 30, 2021:
For the nine- months ended September 30, | For the nine- months ended September 30, | |||||||||||||||
| Sale of Product | 2022 | 2021 | $ change | % change | ||||||||||||
| Radiochemical Products | $ | 4,304,629 | $ | 3,100,001 | $ | 1,204,628 | 39 | % | ||||||||
| Cobalt Products | 695,783 | 1,104,176 | (408,393 | ) | -37 | % | ||||||||||
| Nuclear Medicine Standards | 3,031,110 | 3,135,970 | (104,860 | ) | -3 | % | ||||||||||
| Fluorine Products | — | 29,775 | (29,775 | ) | 0 | % | ||||||||||
| Total Consolidated | $ | 8,031,522 | $ | 7,369,922 | $ | 661,600 | ||||||||||
Gross profit for the nine-month period ended September 30, 2022 was $4,560,816, compared to $4,360,266, for the same period in 2021. This represents an increase of $200,550 or approximately 5%.
The following table presents cost of sales and gross profit data for each of our business segments for the nine months ended September 30, 2022 and 2021:
For the nine- months ended September 30, | % of Total Sales | For the nine- months ended September 30, | % of Total Sales | |||||||||||||
| 2022 | 2022 | 2021 | 2021 | |||||||||||||
| Total Sales | $ | 8,031,522 | $ | 7,369,922 | ||||||||||||
| Cost of Sales | ||||||||||||||||
| Radiochemical Products | $ | 1,567,097 | 19 | % | $ | 1,251,953 | 17 | % | ||||||||
| Cobalt Products | 315,204 | 4 | % | 456,056 | 6 | % | ||||||||||
| Nuclear Medicine Standards | 1,588,405 | 20 | % | 1,301,647 | 18 | % | ||||||||||
| Fluorine Products | — | 0 | % | — | 0 | % | ||||||||||
| Total Segments | 3,470,706 | 43 | % | 3,009,656 | 41 | % | ||||||||||
| Gross Profit | $ | 4,560,816 | $ | 4,360,266 | ||||||||||||
| Gross Profit % | 57 | % | 59 | % | ||||||||||||
Operating expenses were $5,762,521 for the nine-month period ended September 30, 2022, compared to $4,794,650 for the same period in 2021. This represents an increase of $967,871, or approximately 20%. This increase is primarily due to an approximate 30% increase in Salaries and Contract Labor costs and a 142% increase in Research and Development costs. The increase in Salaries and Contract Labor costs is a result of increased equity-based compensation and increases to labor rates incurred during the nine months ended September 30, 2022, as compared to the same period in 2021. The increase in Research and Development cost is due to increased activity in product development during the nine months ended September 30, 2022, as compared to the same period in 2021.
The following table shows total operating expenses for the nine-month period ended September 30, 2022 and 2021:
For the nine- months ended September 30, | For the nine- months ended September 30, | |||||||||||||||
| Operating Costs and Expenses: | 2022 | 2021 | % change | $ change | ||||||||||||
| Salaries and Contract Labor | $ | 2,535,771 | $ | 1,944,013 | 30 | % | $ | 591,758 | ||||||||
| General, Administrative and Consulting | 2,784,367 | 2,667,535 | 4 | % | 116,832 | |||||||||||
| Research and Development | 442,383 | 183,102 | 142 | % | 259,281 | |||||||||||
| Total operating expenses | $ | 5,762,521 | $ | 4,794,650 | 20 | % | $ | 967,871 | ||||||||
Other income was $2,077,719 for the nine months ended September 30, 2022, as compared to $229,559 for the same period in 2021. This is an increase of $1,848,160, or approximately 805%, primarily due to a $1,797,978 gain on sale of assets to Pharmalogic Idaho, LLC. In February 2022, we entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which we sold certain assets for $4,000,000 in cash. The assets consisted primarily of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company.
| 22 |
Interest expense for the nine months ended September 30, 2022 was $465,260, compared to $601,291 for the same period in 2021. This is a decrease of $136,031, or approximately 23%. Interest expense includes dividends accrued on our Series C Preferred Stock. For the nine months ended September 30, 2022, we accrued dividends payable of $182,835 which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $79,644 for the accretion of the beneficial conversion feature of the 2019 Promissory Note and $112,555 for the issuance of warrants in conjunction with the 2019 Promissory Note were recorded for the nine months ended September 30, 2022. See Note 7 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.
Our net income for the nine months ended September 30, 2022, was $414,328, compared to net loss of $919,408, for the same period in 2021. This is an increase in income of $1,333,736 is largely the result of the approximate $1.8 million gain on sale of assets. Additionally, the increase in income is the result of the increase in revenue in our Radiochemical Products segment offset by the increase in operating expense from salaries and contract labor and expenses from research and development for the nine months ended September 30, 2022, as compared to the same period in 2021.
Radiochemical Products. Revenue from the sale of Radiochemical Products for the nine-month period ended September 30, 2022, was $4,304,629 compared to $3,100,001 for the same period in 2021. This is an increase of $1,204,628, or approximately 39%. The increase is the result of increased sales to most of our customers and further enhanced by a reduction in sales by our competitor in the first quarter of 2022. The reduction in sales by our competitor resulted from a short-term shutdown of a European reactor facility that normally supplied their sodium iodide I-131 during the first quarter of 2022. The increase is also the result of increased sales of our new generic sodium iodide I-131 drug product. We expect continued sales growth for our Radiochemical Products going forward.
Cost of sales was $1,567,097 for the nine-month period ended September 30, 2022, and $1,251,953 for the same period in 2021. This is an increase of $315,144, or approximately 25%. This increase is primarily the result increased sales for the period.
Gross profit percentages for our Radiochemical Products for the nine months ended September 30, 2022 and 2021 were approximately 64% and 60%, respectively. This increased gross profit percentage is a result of increased sales of our new generic sodium iodine I-131 drug product, which carries a higher gross margin, and continued improvements of utilization of raw materials. Operating expense for this segment for the nine-month period ended September 30, 2022 was $1,104,994, compared to $1,068,580 for the same period in 2021. This is an increase of $36,414, or approximately 3%, and is primarily due to increased costs for labor costs, production supplies, advertising expense, and professional services. As discussed above, other income from the Radiochemical Products segment included a $1,797,978 gain on sale of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company. Net income for this segment increased to $3,430,516 for the nine-month period ended September 30, 2022, from $779,468 for the same period in 2021. This increase of $2,651,048, or approximately 340%, is the result of the gain on sale of assets and the 39% increase in revenue.
Cobalt Products. Revenues from the sale of Cobalt Products for the nine-month period ended September 30, 2022 were $695,783, compared to $1,104,176 for the same period in 2021. This is a decrease of $408,393, or approximately 37%, and is the result of decreased cobalt sealed source manufacturing and cobalt recycling. The decrease was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at somewhat random times throughout the year. Frequently the timing of these sales can have a significant impact on period over period comparisons.
During 2015, we entered into cobalt-60 supply agreements with several customers. The terms of the agreements required pre-payments to secure cobalt material in future years. Those prepayments were recorded as unearned revenue on our condensed consolidated balance sheet.
Cost of sales for the nine months ended September 30, 2022, was $315,204, as compared to $456,056, for the same period in 2021. Gross profit for cobalt products for the nine months ended September 30, 2022 was $380,579 compared to $648,120 for the same period in 2021. This is a decrease of $267,541, or 41%. Our gross profit percentages were approximately 55% and 59% for the nine-month periods ended September 30, 2022 and 2021, respectively. Operating expense in this segment increased to $570,030 for the nine months ended September 30, 2022, from $302,828 for the same period in 2021. This is an increase of $267,202, or approximately 88% is mainly the result of approximately $215,000 of waste disposal expenses in 2022 as compared to no such expense in 2021. Additionally, increased labor expenses and production supply costs contributed to the increase in operating expenses in the nine months ended September 30, 2022 as compared to the same period in 2021. Our net loss for Cobalt Products was $189,451 for the nine months ended September 30, 2022, as compared to a net income of $345,292 for the same period in 2021. The decrease in net income of $534,743 or approximately 155%, was attributable to the decreased cobalt sealed source manufacturing sales and increased operating expenses for the nine months ended September 30, 2022, as compared to the same period in 2021.
| 23 |
Nuclear Medicine Standards. Revenue from Nuclear Medicine Standards for the nine-month period ended September 30, 2022 was $3,031,110 compared to $3,135,970 for the same period in 2021. This represents a decrease in revenue attributable to this segment of $104,860, or approximately 3%. The decrease in sales for the period ended September 30, 2022 was due partly to continued slow demand of nuclear medicine imaging products resulting from the continued adverse impact of COVID-19 upon our customers and clinics during the nine months ended September 30, 2022.
Gross profit for the nine-month period ended September 30, 2022 was $1,442,705, as compared to $1,834,323 for the same period in 2021, a decrease of $391,618, or approximately 21%. Operating expense for this segment for the nine-month period ended September 30, 2022 increased to $1,365,962, from $1,327,733 for the same period in 2021. This is an increase of $38,229 or approximately 3% and is the result of increased waste disposal costs in the nine months ended September 30, 2022. Operating expenses include consolidated non-controlling member interest expense of $0 for the nine months ended September 30, 2022, compared to $116,816, for the nine months ended September 30, 2021. Net income for this segment for the nine-month period ended September 30, 2022, decreased to $76,743, approximately 85%, from $506,590 for the same nine-month period in 2021. This decrease is due to increased costs for supplies and raw materials attributable to cost inflation.
Radiological Services. Starting in 2022, due to drastically decreased activity in the segment, all remaining activities in our Radiological Services is reported in our Nuclear Medicine Standards segment.
In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service substantially occurred in 2021 and the Company saw a steady decline in revenue from this service as production was wrapped up. In the first half of 2022, we have converted the spaces in the facility that had been used to perform this contract work into expanded Nuclear Medicine new product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.
Revenue from field service work for the DOE had accounted for the majority of revenue in this segment. However, Radiological Field Services did not generate any Radiological Services segment sales in 2022 or 2021. This was the result the removal of this activity from our NRC license.
Fluorine Products. For the nine months ended September 30, 2022, we had no revenue related to Fluorine Products compared to $29,775, for the same period in 2021. These revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. During the nine months ended September 30, 2022, we incurred $111,377 of expenses related to items in support of future planning and design for the proposed de-conversion facility, as compared to $121,500 for the same nine-month period in 2021. This is a decrease of 8% in the period-to-period comparison.
We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our Fluorine Extraction Process (“FEP”). We will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2022, we had cash and cash equivalents of $2,989,236 as compared to $474,851 at December 31, 2021. This is an increase of $2,514,385 or approximately 530%. For the nine months ended September 30, 2022, net cash used in operating activities was $957,163 and for the nine months ended September 30, 2021, net cash provided by operating activities was $64,294. The increase in cash used in operating activities was a result of increased accounts receivable due to increased revenue. The increase in cash and cash equivalents at period end in the period-to-period comparison is the result of proceeds from sales of property, plant, and equipment.
Inventories at September 30, 2022 totaled $879,210, and inventories at December 31, 2021 totaled $924,775. Our inventory consists of work in process material for our Radiochemical Products, Cobalt Products, and Nuclear Medicine Products segments.
Cash provided by investing activities was $3,931,725 for the nine months ended September 30, 2022, and cash used in investing activities was $196,730 for the same period in 2021. The cash provided by investing activities in the nine months ended September 30, 2022 was mainly for the sale of assets for $4,000,000. In February 2022, we entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which we sold certain assets for $4,000,000 in cash. The Assets consisted primarily of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company. The cash used in investing activities in the nine months ended September 30, 2021 was for purchase of equipment.
| 24 |
Financing activities used cash of $456,759, during the nine months ended September 30, 2022, and cash used in financing activities for the same period in 2021 was $34,994. During the nine months ended September 30, 2022, cash paid for interest was $49,699 and during the same nine-month period in 2021, cash paid for interest was $69,042. Additionally, during the nine months ended September 30, 2022, we received $12,305 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan and $61,800 for exercise of warrants, as compared to $13,527 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan for the same period in 2021. During the nine months ended September 30, 2022, principal payments on notes payable were $524,532, as compared to $390,571 for the same period in 2021. This increase in principal payments was largely due to payment in full of the 2021 Promissory Note as described below.
In February 2022, the Company paid its third annual dividend on the Series C Preferred Stock. Dividends paid totaled $243,780. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 2,271,980 shares of common stock in lieu of a dividend payment of $204,480. The remaining $39,300 of dividend payable was settled with cash.
Total increase in cash for the nine-month period ended September 30, 2022, was $2,517,803 compared to a cash decrease of $167,430 for the same period in 2021.
We expect that cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and preferred stock shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.
At September 30, 2022, there were no outstanding warrants to purchase our common stock.
Debt
In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In June 2014, pursuant to a modification, the maturity date was extended to December 31, 2017. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged. In January 2022, the 2013 Promissory Note was modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. At September 30, 2022, accrued interest payable on the 2013 Promissory Note totaled $264,234.
In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged. In December 2021, the 2018 Promissory Note was modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. At September 30, 2022, accrued interest on the 2018 Promissory Note totaled $31,970.
In December 2019 and February 2020, we borrowed $1,000,000 from our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders pursuant to a promissory note (the 2019 Promissory Note). The 2019 Promissory Note bears an interest rate of 4% annually and is due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. At September 30, 2022, the balance of the 2019 Promissory Note was $1,000,000, The remaining debt discount was $37,518, the remaining beneficial conversion feature was $26,548, and the accrued interest on the 2019 Promissory Note totaled $109,131.
| 25 |
In April 2021, we borrowed $250,000 from its Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2021 Promissory Note). The 2021 Promissory Note accrued interest at 6% per annum, which was payable upon maturity of the 2021 Promissory Note. The 2021 Promissory Note was originally secured and was to mature on December 31, 2022. At any time, the holders of the 2021 Promissory Note were able to elect to have any or all of the principal and accrued interest settled with shares of our common stock at a conversion price of $0.11 per share. On March 31, 2022, the Company repaid the 2021 Promissory Note in full. The payment included $250,000 in principal and $14,500 in interest.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
From time-to-time, management reviews and evaluates certain accounting policies and estimates that are considered to be significant in determining our results of operations and financial position.
A description of the Company’s critical accounting policies and estimates that affect the preparation of the Company’s financial statements is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022.
| 26 |
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of September 30, 2022, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2022.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A discussion of legal matters is found in Note 8, “Commitments and Contingencies”, in the accompanying notes to the unaudited condensed consolidated financial statements included in Part I - Item 1. Financial Statements of this Quarterly Report.
ITEM 1A. RISK FACTORS
There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
| 27 |
ITEM 6. EXHIBITS
| Exhibit No. | Description |
| 3.1 | Restated Certificate of Formation, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q for quarter ended June 30, 2010). |
| 3.2 | Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 24, 2017). |
| 3.3 | Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock International Isotopes Inc., dated February 16, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 22, 2022). |
| 3.4 | Bylaws (incorporated by reference to Exhibit 3.2 of the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)). |
| 31.1* | Certification by the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification by the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification by the Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification by the Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). |
_______________
* Filed herewith.
** Furnished herewith.
| 28 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 14, 2022 | International Isotopes Inc. | |
| By: | /s/ Steve T. Laflin | |
| Steve T. Laflin | ||
| President and Chief Executive Officer | ||
| By: | /s/ W. Matthew Cox | |
| W. Matthew Cox | ||
| Chief Financial Officer | ||
29